Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers

Prostate

Volumn 43, Issue 3, 2000, Pages 233-242

  Nguyen, TuDung T ^a   Nguyen, Carvell T ^a   Gonzales, Felicidad A ^a   Nichols, Peter W ^a   Yu, Mimi ^a   Jones, Peter A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cyclin dependent kinase inhibitor; DNA methylation; p16; RB

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN P15; PROTEIN P16;

ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; DNA METHYLATION; ENZYME INHIBITORS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0034013724     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000515)43:3<233::AID-PROS10>3.0.CO;2-S     Document Type: Article

References (61)

1. Kallio PJ, Palvimo JJ, Janne OA. Genetic regulation of androgen action. Prostate [Suppl] 1996;6:45-51.
2. Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995;23:43-62.
3. Feldman D, Skowronski RJ, Peehl DM. Vitamin D and prostate cancer. Adv Exp Med Biol 1995;375:53-63.
4. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
5. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med 1997;3:5-20.
6. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-692.
7. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen TD, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-4535.
8. Cairns P, Polascik TJ, Eby Y, Tokino K, Califani J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D, Sidransky D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat Genet 1995;11:210-212.
9. Quesnel B, Preudhomme C, Fenaux P. p16ink4a gene and hematological malignancies. Leuk Lymphoma 1996;22:11-24.
10. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995;86:841-854.
11. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D, Baylin SB. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-4530.
12. Liu A, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK, Kamb A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 1995;10:1061-1067.
13. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J. Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 1995;86:622-625.
14. Chen W, Weghorst CM, Sobourin CLK, Wang Y, Wang D, Bostwick DG, Stoner GD. Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 1996;17:2603-2607.
15. Tamimi Y, Bringuier PP, Smit F, van Bokhoven A, Debruyne FMJ, Schalken JA. p16 mutations/deletions are not frequent events in prostate cancer. Br J Cancer 1996;74:120-122.
16. Konishi N, Hiasa Y, Tsuzuki T, Matsuda H, Tao M, Nakamura M, Naito H, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J, Lin J-C. Detection of RB, p16/CDKN2 and p15INK4B gene alterations with immunohistochemical studies in human prostate carcinomas. Int J Oncol 1996;8:107-112.
17. Gu K, Mes-Masson A-M, Gauthier J, Saad F. Analysis of the p16 tumor suppressor gene in early-stage prostate cancer. Mol Carcinog 1998;21:164-170.
18. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83: 993-1000.
19. INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994;371:257-261.
20. Haber DA. Splicing into senescence: the curious case of p16 and p19ARF. Cell 1997;91555-558.
21. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-659.
22. Knabbe C, Klein H, Zugmaier G, Voigt KD. Hormonal regulation of transforming growth factor beta-2 expression in human prostate cancer. J Steroid Biochem Mol Biol 1993;47:137-142.
23. Hoodless PA, Wrana JL. Mechanism and function of signaling by the TGF beta superfamily. Curr Top Microbiol Immunol 1998;228:235-272.
24. Perry KT, Anthony CT, Case T, Steiner MS. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 1997;49:151-155.
25. Steiner MS, Barrack ER. Transforming growth factor-beta 1 over-production in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
26. Thompson TC, Troung LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino FT, Park SH. Transforming growth factor beta1 as a biomarker for prostate cancer. J Cell Biochem [Suppl] 1992;16:54-61.
27. Steiner M, Zhou Z-Z, Tonb DC, Barrack ER. Expression of transforming growth factor-beta1 in prostate cancer. Endrocinology 1994;135:2240-2247.
28. Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-beta1 and bcl-2 expression. Int J Cancer 1996;69:357-363.
29. Hering S, Surig D, Freystadt D, Schatz H, Pfeiffer A. Regulation of transforming growth factor beta by sex steroids. Horm Metab Res 1995;27:345-351.
30. Zhuang SH, Burnstein K. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998;139:1197-1207.
31. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10:142-153.
32. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-11737.
33. Lee WH, Isaacs WB, Bova GS, Nelson WG. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev 1997;6: 443-450.
34. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, Simons JW. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-668.
35. Nelson JB, Lee WH, Nguyen SH, Jarrard DF, Brooks JD, Magnuson SR, Opgenorth TJ, Nelson WG, Bova GS. Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res 1997;57:35-37.
36. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
37. Gonzalgo ML, Hayashida T, Bender CM, Pao MM, Tsai YC, Gonzales FA, Nguyen HD, Nguyen TT, Jones PA. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998;58:1245-1252.
38. Gonzalgo M, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res 1997;25:2529-2531.
39. Gonzalgo ML, Bender CM, You EH, Glendening M, Flores JF, Walker GJ, Hayward NK, Jones PA, Fountain JW. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res 1997;57:5336-5347.
40. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997;25:2532-2534.
41. Snedecor GW, Cochran WG. Statistical methods. Sixth edition. Ames, IA: Iowa State University Press; 1967.
42. Meikle AW, Stanish WM. Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 1982;54:1104-1108.
43. Narod SA, Dupont A, Cusan L, Diamond P, Gomez J-L, Suburu R, Labrie F. The impact of family history on early detection of prostate cancer. Nat Med 1995;1:99-101.
44. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-506.
45. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 1996;56:722-727.
46. Halvorsen OJ, Haukaas S, Hoisaeter PA, Akslen LA. Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia, and benign/hyperplastic glands. Urol Oncol 1997;3:59-66.
47. Wang E. Senescent human fibroblasts resist programmed cell death and failure to suppress bcl2 is involved. Cancer Res 1995; 55:2284-2292.
48. Campisi J. Aging and cancer: the double-edged sword of replicative senescence. J Am Geriatr Soc 1997;45:482-488.
49. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996;16:859-867.
50. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998;8:351-354.
51. Shapiro GI, Edwards CD, Kobzik L, Godleski H, Richards W, Sugarbaker DJ, Rollins BJ. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 1995;55:505-509.
52. Knudsen ES, Pazzagli C, Born TL, Bertolaet BL, Knudsen KE, Arden KC, Henry RR, Feramisco JR. Elevated cyclins and cyclindependent kinase activity in the rhabdomyosarcoma cell line RD. Cancer Res 1998;58:2042-2049.
53. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRB alterations in human urothelial cells. Cancer Res 1995;55:493-497.
54. Parry D, Bates S, Man DJ, Peters G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 1995;14:503-511.
55. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 1995;27:314-320.
56. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee W-H. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990;87:7762-7766.
57. Phillips SMA, Barton CM, Lee SJ, Morton DG, Wallace DMA, Lemoine NR, Neoptolemos JP. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994;70:1252-1257.
58. Brooks JD, Bova S, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995;26:35-39.
59. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, Ben-Neriah Y. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1994;91:10722-10726.
60. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995;55:5195-5199.
61. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998;95: 5246-5250.